Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 15, 2019. The document serves as an announcement regarding the extension of a cash tender offer for TESARO, Inc. (TESARO), initiated by GSK's indirect wholly-owned subsidiary, Adriatic Acquisition Corporation (AAC).
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity for GSK. The only quantitative data provided relates to the tender offer status:
- Shares Tendered: 46,743,017 shares as of January 14, 2019.
- Percentage of Outstanding Shares: Approximately 77.2% of issued and outstanding shares.
- Condition Precedent: Completion requires the tender of at least one share more than 50% of issued and outstanding shares.
Material Changes
The primary material change is the extension of the tender offer expiration date:
- Previous Expiration: January 14, 2019, at 11:59 P.M. Eastern Time.
- New Expiration: January 18, 2019, at 6:00 P.M. Eastern Time (unless further extended).
- Reason for Extension: To allow for the expiration of statutory review periods under the German Act against Restraints of Competition (expiring January 18) and the Austrian Cartel Act (expiring January 15).
Outlook, Risks, and Contingencies
Outlook and Management Commentary: GSK and AAC expect the tender offer to be consummated promptly following the extended expiration date, subject to the satisfaction of remaining conditions. Stockholders who have already tendered shares do not need to take further action.
Risks and Contingencies:
- Regulatory Approval: The transaction is contingent upon the expiration of regulatory review periods in Germany and Austria.
- Minimum Tender Condition: The offer is conditioned on receiving tenders for more than 50% of outstanding shares.
- Forward-Looking Statements: GSK cautions that actual results may differ materially from projections due to risks described in its 2017 Annual Report on Form 20-F.
Investor Verification Checklist
- Verify the final tender percentage to ensure it exceeds the 50% threshold required for consummation.
- Confirm the status of regulatory approvals from German and Austrian authorities by the January 18 deadline.
- Review the Schedule TO filed with the SEC on December 14, 2018, for other conditions to the consummation of the tender offer.
- Check for any further extensions to the tender offer expiration date beyond January 18, 2019.